Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427
Status:
Recruiting
Trial end date:
2022-05-17
Target enrollment:
Participant gender:
Summary
This first-time-in-human (FTIH) study will be conducted to evaluate the safety, tolerability,
pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single doses of AZD3427
in healthy volunteers and multiple doses of AZD3427 in patients with heart failure (HF).